 |
인쇄하기
취소
|
Iressa Proven for Extended Survival Rates among Asians
AstraZeneca Korea recently announced the results from the first-level intermediate analysis of ISEL (Iressa Survival Evaluation in Lung cancer) Study, an international clinical trial conducted against 1,692 patients with different racial backgrounds.
According to the analysis, the cancer patients in the Asian subgroup receiving Iressa (active ingredient: gefinitib) showed a higher duration o...
According to the analysis, the cancer patients in the Asian subgroup receiving Iressa (active ingredient: gefinitib) showed a higher duration o...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.